Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
The BBRSC Programme combines Chemistry and Biochemical Engineering at UCL with Almac’s Biocatalysis Group.

The Almac biocatalysis group has secured a prestigious BBSRC (Biotechnology and Biological Sciences Research Council) programme with UCL focused specifically on metagenomics and novel enzyme discovery. The R&D work concerned is set to be carried out jointly between Almac and the departments of Biochemical Engineering and Chemistry at UCL, with high level input from two world leaders in the field of biocatalyst discovery and application, Professors John Ward and Helen Hailes.

Dr. Tom Moody, Almac’s Head of Biocatalysis & Isotope Chemistry, commented “This clearly adds further depth to our expertise and complements our recent collaboration with DSM in accessing diverse enzyme collections.”

Professor Ward remarked: “We are very excited to continue working with Almac on this prestigious project, building on many years of collaboration and partnership. Indeed, this project will see our internal capabilities further developed with true industrial needs in our vision.”

The application of biocatalysis technology to the pharmaceutical and fine chemical industries is continuing to grow year on year and this trend is mirrored in the increasing number of synthetic projects being carried out by the biocatalysis group in Almac.

The only limitation of biocatalysis is in the number of diverse enzymes available in a given enzyme class, which dictates both the substrate range and the stereoselectivity observed for a desired chemical transformation. The majority of enzymes used in biocatalysis are derived from microbial sources. However, it is known that only a tiny percentage (as low as 0.1% from soil samples) of bacteria present in an environmental sample can be cultured and isolated.

Metagenomics, a culture-independent technique used to extract the total DNA from an environment, can circumvent this problem and allow access up to 99% of enzyme genes present in environmental samples. Work previously carried out at UCL has allowed a series of metagenomes to be obtained from various unusual sources. The use of bioinformatic tools developed by John Ward with Prof Christine Orengo of the Structural and Molecular Biology department at UCL will allow the metagenomes concerned to be mined for enzymes usable in both synthetic chemistry and synthetic biology projects.

Moody further commented “The need for more diverse enzymes has never been greater and this research programme further emphasises Almac’s commitment to UK research and to biocatalysis development.”

He continued; “The project will mainly focus on transaminase and cytochrome P450s enzymes. We will   identify, clone and express these enzymes before carrying out extensive screening against panels of ‘typical’ pharmaceutical and fine chemical substrates. This should enable us   to identify novel and commercially useful enzyme biocatalysts. As the follow-on step, directed evolution at Almac will enable further development of the lead enzymes concerned.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Richard Segiel, Jr. Joins Almac as Vice President of US Business Development
Richard will focus on developing new business, maintaining existing business, and developing partnerships.
Wednesday, October 30, 2013
Todd Kole Appointed to Almac’s Clinical Technologies Executive Team
Todd will oversee clinical project management and drug supply services globally.
Tuesday, August 30, 2011
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!